Asymchem Laboratories (Tianjin) (002821) Q3 2025 earnings summary

Executive summary

• Revenue for the first three quarters of 2025 reached ¥4.63 billion, up 11.82% year-over-year, with new business segments showing strong growth.

• Net profit attributable to shareholders for the period was ¥800.25 million, up 12.66% year-over-year, despite a 13.46% decline in Q3 net profit compared to the same quarter last year.

• New business segments such as peptides, oligonucleotides, and ADCs saw significant market expansion and double-digit order growth.

Financial highlights

• Q3 revenue: ¥1.44 billion, down 0.09% year-over-year; Q3 net profit: ¥182.77 million, down 13.46% year-over-year.

• Gross margin for the first three quarters was 42.44%; small molecule business margin at 46.99%, emerging business margin at 30.55%, up 10.57 percentage points year-over-year.

• Basic and diluted EPS for Q3: ¥0.50, down 18.03% year-over-year; YTD EPS: ¥2.18, up 8.46% year-over-year.

• Net cash from operating activities for the first three quarters: ¥1.14 billion, up 8.67% year-over-year.

Outlook and guidance

• Full-year revenue is expected to grow 13–15%, with Q4 delivery scale projected to be significantly higher than Q3.